Alternate Name(s):
TRANDATE®
Classification:
Antihypertensive agent
Original Date:
August 2005
Revised Date:
July 2026
Indications:
- Treatment of severe hypertension and hypertensive emergencies
- Blood pressure management with reperfusion therapy
Reconstitution and Stability:
- Available as a 5 mg/mL solution
- Store at room temperature
- Protect from light
- Stable for 72 hours in compatible IV solutions at room temperature or refrigerated
Compatibility:
- Solutions Compatible: D5W, NS, dextrose-saline combinations, ringer's solution, ringer's lactate
- Additives/Above Cassette Compatible: no information
- Y-site Compatible: amiodarone, dobutamine, esmolol, KCl, meperidine, morphine, norepinephrine, propofol
- Incompatible: amphotericin, ceftriaxone, furosemide, sodium bicarbonate
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct |
YES; cardiac monitoring and continuous BP monitoring Critical care areas only |
| IV Intermittent Infusion |
NO |
| IV Continuous Infusion |
YES cardiac monitoring, BP monitoring |
Click here to access SDC Drug Infusion Sheet
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
Hypertensive Emergency
IV Direct:
- 0.2-1 mg/kg/dose IV every 10 minutes as needed
- Maximum: 40 mg/dose
Continuous IV infusion:
- Initial: 0.25 - 1 mg/kg/hour
- Titrate by increments of 0.25 to 0.5 mg/kg/hour as needed to control BP
- Maximum: 3 mg/kg/hour (rates up to 8 mg/hour have been used)
Acute Ischemic Stroke (BP management with reperfusion therapy)
IV Direct:
- 0.5 mg/kg/dose IV every 10 minutes as needed to maintain systolic blood pressure within target
- Maximum: 40 mg/dose
- After 3 doses have been given and desired BP is not achieved, switch to continuous infusion
Continuous Infusion:
- Initial: 0.5-1 mg/kg/hour
- Titrate by increments of 0.5 mg/kg/hour every 10 minutes to maintain systolic blood pressure within target
- Maximum: 3 mg/kg/hour (rates up to 8 mg/hour have been used)
Potential hazards of parenteral administration:
- Postural hypotension, dizziness
- Nausea/vomiting, drowsiness, fatigue, paresthesias (especially scalp tingling)
- Bronchospasm
- Bradycardia
- Somnolence, vertigo
Notes:
- Contraindicated in asthma, obstructive airway disease, greater than first degree heart block, cardiogenic shock, severe bradycardia, uncontrolled CHF, pulmonary edema
- Caution in patients with diabetes mellitus (masks signs of hypoglycemia), impaired hepatic function (metabolized in liver) and pheochromocytoma (paradoxical hypertensive responses)
- Additive hypotensive response may occur with halothane or isoflurane anesthesia
- Patients should remain supine during and for up to three hours after IV administration
- Monitor blood pressure, heart rate, pulse, EKG
- Onset: 2-5 minutes; duration: 2-4 hours